Newscast – Page 151 – media

Cancer cells destroyed in just 3 days with new technique

Cancer cells are relentless, possessing the vexatious ability to develop resistance to current therapies and making the disease hugely challenging to treat. However, an exciting new study may have identified cancer's weak spot; the discovery has already led to the near-eradication of the disease in cell cultures.
- Source: medicalnewstoday
- 686
- November 8, 2017
cancer cell chromatin Researches
Low vitamin D may raise risk of kidney failure

New research, conducted by scientists at the Johns Hopkins University School of Medicine in Baltimore, MD, finds that low vitamin D raises the risk of organ damage and renal disease in people with lupus – an autoimmune disease.
- Source: medicalnewstoday
- 1,068
- November 8, 2017
autoimmune inflammation lupus Researches SLE vitamin
Black Death and incurable Marburg Virus now spreading across Africa’s cities

Africa is currently contending with two serious disease outbreaks. The pneumonic plague has been making headlines as it sweeps across Madagascar, but there are concerns about it are being eclipsed by a far more sinister threat: A rare and fatal virus known Marburg virus disease (MVD), which has now broken out in Uganda.
- Source: naturalnews
- 1,163
- November 8, 2017
Market Views MVD pneumonic plague WHO
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

The U.S. Food and Drug Administration(FDA) has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
- Source: Worldpharmanews
- 451
- November 8, 2017
BRAF V600 ECD FDA Zelboraf (vemurafenib)
Increasing rates of chronic conditions putting more moms, babies at risk

Pregnant women today are more likely to have chronic conditions that could cause life-threatening complications than at any other time in the past decade - particularly poor women and those living in rural communities, a new Michigan Medicine study suggests.
- Source: Medicalxpress
- 395
- November 8, 2017
chronic conditions Researches
Merck, Pfizer launch Bavencio for rare skin cancer

Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
- Source: Pharmatimes
- 496
- November 7, 2017
avelumab Company Insight mMCC skin cancer
Moderna Announces New Collaboration with AstraZeneca

Moderna Therapeutics today announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize a messenger RNA (mRNA) therapeutic encoding for Relaxin. The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
- Source: Modernatx
- 470
- November 7, 2017
heart Market Views mRNA
Just two sugary drinks per week may raise type 2 diabetes risk

The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
- Source: medicalnewstoday
- 603
- November 7, 2017
cardiometabolic diabetes Market Views WHO
Men with low testosterone less likely to have prostate cancer

New research suggests that men with abnormally low levels of testosterone are less likely to develop prostate cancer in their lifetime. The new study was carried out by scientists at the University of Oxford in the United Kingdom, and the findings were presented at the National Cancer Research Institute (NCRI) Cancer Conference, held in Liverpool, U.K.
- Source: medicalnewstoday
- 580
- November 7, 2017
cancer NCRI prostate Researches testosterone
Scientists discover potential treatment to stop glaucoma in its tracks

Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
- Source: Medicalxpress
- 497
- November 7, 2017
glaucoma lipid mediators neurodegenerative disease

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.